COMPANY PROFILE

Hyasynth Bio

Explore full profile

Make strains of yeast that produce cannabinoids

Montreal, CanadaFounded 2014Biotech & Life Sciences

Valuation $25–50M Last recorded · 2020

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Hyasynth Bio

Hyasynth Bio is a biotechnology company specializing in the biosynthesis of cannabinoids, which are compounds found in cannabis plants. The company operates in the pharmaceutical and wellness markets, focusing on producing rare cannabinoids through fermentation technology. This method is more sustainable and scalable compared to traditional plant extraction. Hyasynth Bio serves pharmaceutical companies, wellness product manufacturers, and other industries that require high-quality cannabinoids. The business model revolves around licensing its biosynthesis technology and selling the cannabinoids produced. Revenue is generated through milestone payments, licensing fees, and direct sales of cannabinoids. The company has achieved significant milestones, including the production of 20 rare cannabinoids and securing patents for its technology. Hyasynth Bio is backed by investors like Organigram Holdings Inc., which supports its commercialization efforts.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: Montreal, Canada
Employees: 5
Open positions: None listed
Dealroom signal: 67.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Producer, Synthetic Biology, Biotech and Pharma, Fermentation, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b, b2c
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
DEBTDebt	Dec 2021	$2.5M	—	OrganiGram	—
LATE VC✓Equity / VC	Oct 2020	$2.5M	$38M	OrganiGram	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Hyasynth Bio website traffic

Latest recorded traffic for Hyasynth Bio is 250 monthly website visits, up 47.1% over the last three months. Hyasynth Bio's team grew 0% over the past year.

Latest monthly visits250 3-month web change+47.1% 1-year team growth0%

Monthly website visitsDec 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PBPioneer BiolabsB2B biomanufacturing company leveraging its proprietary genomic screening platform to engineer and optimize microbial cells for protein production	Provo, United States	Operational	4	—	—
PHPhyx44Creating nature-identical, cell derived alternatives to dairy products	Bengaluru, India	Operational
TUTurtleTreeCreating real milk in full composition, functionality, and taste using cell-based tech	Sacramento, United States	Operational
APAmai ProteinsProduces protein ingredients for food and beverage: the first focus is sweet 'designer' proteins as sugar substitutes	Rehovot, Israel	Operational
EBEXO BiologicsNovel nanomedicine platform for rare disease therapeutics	Liège, Belgium	Operational
ABAtrandi BiosciencesMaking droplet microfluidics easy-to-use and accessible for cutting-edge research	Vilnius, Lithuania	Operational
OFOfficinaeEmpowering innovators to design and manufacture products built with biology	Venice, Italy	Operational
ATAurealis TherapeuticsA Swiss-Nordic synthetic biology company developing ground-breaking cell and gene therapies	Kuopio, Finland	Operational